[Form 4] Zentalis Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Zentalis Pharmaceuticals (ZNTL) Director Jan Skvarka received a grant of 57,603 restricted stock units (RSUs) on June 17, 2025, as part of the company's Non-Employee Director Compensation Program. Following this transaction, Skvarka now beneficially owns 207,154 shares directly.

Key details of the RSU grant:

• Each RSU represents a contingent right to receive one share of common stock
• Vesting occurs at the earlier of June 17, 2026 or the next annual stockholder meeting
• Vesting is contingent on continued service on the Board of Directors
• The RSUs were granted at $0 exercise price

This Form 4 filing was submitted by Andrea Paul as attorney-in-fact for Jan Skvarka on June 18, 2025, in compliance with SEC insider trading reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skvarka Jan

(Last) (First) (Middle)

C/O ZENTALIS PHARMACEUTICALS, INC.

10275 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		A		57,603(1)	A	$0	207,154	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Remarks:

	/s/ Andrea Paul, attorney-in-fact for Jan Skvarka	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ZNTL shares did Jan Skvarka acquire on June 17, 2025?

Jan Skvarka acquired 57,603 restricted stock units (RSUs) of Zentalis Pharmaceuticals (ZNTL) common stock on June 17, 2025, as part of the company's Non-Employee Director Compensation Program.

What is the vesting schedule for ZNTL director Jan Skvarka's latest RSU grant?

The RSUs will vest on the earlier of: (a) June 17, 2026, or (b) the next annual meeting of Zentalis Pharmaceuticals' stockholders, subject to Skvarka's continued service on the Board of Directors through the vesting date.

How many ZNTL shares does Jan Skvarka own after the June 17, 2025 transaction?

Following the RSU grant, Jan Skvarka beneficially owns 207,154 shares of ZNTL common stock directly (Form D ownership).

What was the purchase price of ZNTL shares in Skvarka's June 2025 acquisition?

The restricted stock units were granted at $0 cost to Jan Skvarka as part of Zentalis Pharmaceuticals' Non-Employee Director Compensation Program.

What is Jan Skvarka's role at ZNTL according to the Form 4?

According to the Form 4 filing, Jan Skvarka serves as a Director on Zentalis Pharmaceuticals' Board of Directors, as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.